Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Portland, Oregon 97239


Purpose:

This is a randomized, multi-center, parallel-group study to evaluate the pharmacodynamics (PD) of Medroxyprogesterone Acetate (MPA) after a single subcutaneous (SC) injection of 150 mg/mL or 300 mg/2 mL Depo-Provera CI in the abdomen of women of reproductive age with a confirmed ovulatory baseline cycle.


Study summary:

This is a randomized, multi-center, parallel-group study with a primary objective to evaluate the pharmacodynamics (PD) of Medroxyprogesterone Acetate (MPA) after a single subcutaneous (SC) injection of 150mg/mL or 300mg/2mL Depo-Provera CI in the abdomen of women of reproductive age with a confirmed ovulatory baseline cycle. Secondary study objectives are: - To evaluate and compare the pharmacokinetics (PK) of MPA after a single SC injection of 150mg/mL or 300mg/2mL of Depo-Provera CI to two injections of Depo-subQ 104 administered 3 months apart - To evaluate the relationship between serum MPA concentration and suppression of ovulation - To evaluate and compare the safety, tolerability and acceptability of a SC injection of DMPA of different frequencies, doses and volumes


Criteria:

inclusion Women may be included in the study if they meet all of the following criteria: - in good general health - age 18 to 40 years, inclusive - willing to provide informed consent and follow all study requirements - not pregnant - does not desire to become pregnant in the next 24 months - regular menstrual cycle (24 to 35 days) - confirmed ovulation by serum P ≥ 4.7 ng/mL in two consecutive samples during the pre-treatment phase of the study - at low risk of pregnancy (e.g., sterilized, in exclusively same sex partnership, in monogamous relationship with vasectomized partner, abstinent, using non-hormonal IUD or condoms) - has a body mass index of 18.0 to 35.0 - has hemoglobin ≥10.5 g/L exclusion Women will be excluded from participating in this study if they meet any of the following criteria: - medical contraindications to DMPA use - use of any of the following medications within 1 month prior to enrollment: - any investigational drug - prohibited drugs (per protocol) - oral contraceptives - LNG IUS or implant - use of DMPA in the past 12 months - use of a combined injectable contraceptive in the past 6 months - recent pregnancy (within 3 months) - current lactation - ongoing or anticipated use of prohibited drugs (per protocol) - known sensitivity to MPA - plan to move to another location in the next 18 months - any condition (social or medical) which in the opinion of the site investigator would make study participation unsafe, would interfere with adherence to study requirements or complicate data interpretation.


NCT ID:

NCT02456584


Primary Contact:

Study Director
Vera Halpern, MD
FHI 360


Backup Contact:

N/A


Location Contact:

Portland, Oregon 97239
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 23, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.